Drug Trial Radar · NCT05294328
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Last checked: Nov 20, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
May 5, 2022
Primary completion
Aug 22, 2022
Study completion Sep 10, 2022
Sponsor
- Lead sponsor
- LENZ Therapeutics, IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Conditions
- Presbyopia
- Refractive Errors
- Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solutionDrug
LNZ101-combination ophthalmic solution
Aceclidine ophthalmic solutionDrug
LNZ100- aceclidine ophthalmic solution
Vehicle Proprietary Ophthalmic SolutionDrug
Proprietary Vehicle Ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance VisionTime frame: 1 hour post treatment
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
INSIGHT-1 Study Site #4
Glendale, California
INSIGHT-1 Study Site #3
Indianapolis, Indiana
INSIGHT-1 Study Site #1
Andover, Massachusetts
INSIGHT-1 Study Site #2
Memphis, Tennessee
INSIGHT-1 Study Site #5
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.